Shionogi launches tender for control of C&O
This article was originally published in Scrip
Shionogi has launched an unconditional general tender offer for the Chinese company C&O Pharmaceutical Technology (Holdings), in line with its acquisition plan for the Hong Kong-based firm announced a month ago.
You may also be interested in...
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.